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https://doi.org/10.1016/j.stemcr.2018.04.001SUMMARYTo determine the role for mutations ofMECP2 in Rett syndrome, we generated isogenic lines of human induced pluripotent stem cells,
neural progenitor cells, and neurons from patient fibroblasts with and without MECP2 expression in an attempt to recapitulate disease
phenotypes in vitro. Molecular profiling uncovered neuronal-specific gene expression changes, including induction of a senescence-
associated secretory phenotype (SASP) program. Patient-derived neurons made without MECP2 showed signs of stress, including induc-
tion of P53, and senescence. The induction of P53 appeared to affect dendritic branching in Rett neurons, as P53 inhibition restored
dendritic complexity. The induction of P53 targets was also detectable in analyses of human Rett patient brain, suggesting that this
disease-in-a-dish model can provide relevant insights into the human disorder.INTRODUCTION
Rett syndrome is a disease associated with loss of function
mutations in the gene MECP2, which was originally iden-
tified as encoding a methylated DNA binding protein
(Chen et al., 2001; Meehan et al., 1992). Patient symptoms
includemicrocephaly, intellectual disability, facial dysmor-
phia, and seizure activity (Bird, 2008). Studies in murine
models recapitulate many of the patient phenotypes and
have recently identified a role for Mecp2 particularly in
inhibitory neurons (Tomassy et al., 2014). These studies
demonstrated that loss of MECP2 can lead to defects in
transcription (Chen et al., 2003; Lee et al., 2014), dendritic
branching (Zhou et al., 2006), nuclear size (Chen et al.,
2001), and AKT signaling (Li et al., 2013).
MECP2 has also been described as a transcription factor
with specific targets (Chen et al., 2003; Zhou et al., 2006),
and more broadly as either a transcriptional activator (Li
et al., 2013) or repressor (Cross et al., 1997; Nan et al.,
1997). However, despite decades of research on MECP2, it
is still unclear howmutations in this protein lead to patient
symptoms (Chen et al., 2001; Marchetto et al., 2010). To
confirm findings made in other models and further study
these in a human system, some have turned to modeling
Rett syndrome in vitro by taking advantage of disease-in-
a-dish approaches. This involves making human induced
pluripotent stem cells (hiPSCs) from patient somatic cells,
or using genome engineering to introduce mutations into
wild-type (WT) human pluripotent stem cells. In the cur-Stem Cell R
This is an open access article under the Crent study, we also sought to mitigate the effect of genetic
background and variability of differentiation by taking
advantage of several isogenic lines of hiPSCs that either ex-
press theWTallele or the mutant allele leading to cells that
express or lack MECP2 (Tchieu et al., 2010). This allowed
for detailed molecular analyses of hiPSCs, neural progeni-
tor cells (NPCs), and neurons with andwithoutMECP2 un-
der the same genetic background. In comparing neurons
from Rett patients as well as those with MECP2 silenced
by small interfering RNA (siRNA), it is clear that loss of
MECP2 leads to induction of P53 and senescence, poten-
tially opening an avenue of investigation for this intellec-
tual disability syndrome.RESULTS
A Human Model of Rett Syndrome In Vitro
Cognizant of the fact that differentiation from hPSCs is
highly variable across individual lines, culture conditions,
and time, we developed an isogenic model to study Rett
syndrome in vitro to remove the confound of genetic back-
ground (Tchieu et al., 2010). Because female patients with
Rett syndrome are usually heterozygous for mutant alleles
of MECP2, fibroblasts isolated from these patients display
amosaic pattern where roughly half the cells express either
the mutant or WT allele. This is shown in Figure 1A, where
fibroblasts isolated from two patients with distinct mutant
alleles ofMECP2 (R982 and R567) showed that roughly halfeports j Vol. 10 j 1453–1463 j May 8, 2018 j ª 2018 The Author(s). 1453
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the cells expressed MECP2 while the other half lacked
detectable amounts of this protein. Patient descriptions
are provided in Figure S1. Reprogramming to iPSCs using
a small set of transcription factors has been shown to
happen at the clonal level, such that individual reprogram-
ming events in single fibroblasts generate isolated hiPSC
clones (Winkler et al., 2010). Therefore, reprogramming
of mosaic fibroblast cultures from two different patients
generated single hiPSC clones that either expressed
MECP2 protein or lacked it (Figure 1B) (method described
in a previous study; Sahakyan et al., 2016). In addition,
our work and that of others has shown that under standard
conditions, the inactive X chromosome in human fibro-
blasts does not reactivate upon reprogramming to the
pluripotent state (Tchieu et al., 2010), which is distinct
from murine reprogramming (Maherali et al., 2007).
Thus, wewere able to createmultiple lines of hiPSCswith
and without MECP2 from individual patients and thereby
control for differences in genetic background (shown in
Figure 1B are clones made from patient 982; clones from
567 look similar). The hiPSCs generated from fibroblasts
of both patients appeared to be unaffected by the lack of
MECP2, expressed all appropriatemarkers, and successfully
generated teratomas upon injection into the testes of
immunocompromised mice, consistent with previous
hiPSC models for loss of MECP2 (Figure S2A) (Cheung
et al., 2011; Hotta et al., 2009). Lack of MECP2 in patient-
derived cells and specificity of antibody was also confirmed
by western blot (Figure S2B).
Importantly, we never observed reactivation of the
silenced X chromosome that would have resulted in re-
expressionof theWTallele ofMECP2 in any cultures regard-
less of differentiation status or passage. This is consistent
with previous data showing that, despite evidence for
erosion of isolated portions of the silenced X chromosome
(Mekhoubad et al., 2012), many portions of the inactivated
X remain silenced even through reprogramming or differ-
entiation (Patel et al., 2017; Tchieu et al., 2010). Tomeasure
theeffect of anypotentialXCI erosion,weperformedaDNAFigure 1. Generation of the Isogenic Model of Rett Syndrome In
(A) Fibroblasts isolated from Rett syndrome patients (R982 and R56
MECP2 expression due to random XCI.
(B) Multiple isogenic hiPSC lines were produced from patient 982 with
and without MECP2 expression from the same patient, as judged by N
(C) Specification of hiPSCs derived from patient 982 toward neural
without MECP2.
(D) Terminal differentiation of NPCs derived from patient 982 towa
immunostaining for MAP2 and GFAP.
(E) MECP2+ and MECP2 hiPSCs and neurons were assayed by western
downstream target S6.
(F) Sholl assay of dendritic complexity was performed on WT versus M
*p < 0.05 according to Student’s t test. Bar graphs represent means ±methylation analysis on the X chromosome on the lines
from patient 982. This analysis showed that while some
erosion of XCI was detectable across the X chromosome,
there was not a significant difference between any of the
lines (Figure S3A), and methylation at the MECP2 locus
specifically was unchanged between the lines (Figure S3B).
As Rett syndrome primarily afflicts the nervous system
and MECP2 is most highly expressed in neurons, we first
generated NPCs from all of the hiPSCs lines following stan-
dard protocols (Patterson et al., 2012). Across at least two
lines per patient with and without MECP2, we measured
the rate of neuralization, the morphology of NPCs, and
expression of typical marker genes. We were unable to
detect consistent differences in these properties between
multiple clones of both WT and MECP2 null lines derived
from both patients (Figures 1C and S2C). Furthermore,
the growth rate of NPCs with and without MECP2 was
not consistently different in NPCs made from either pa-
tient (Figure S2D). Next, the NPCs were further differenti-
ated by a non-directed differentiation approach that yields
both neurons and glia (growth factor withdrawal; Patter-
son et al., 2012) (Figure 1D). All NPCs from both patients
produced neurons and glia at the same rate (Figures S2E
and S2F).
Previous studies have also shown that loss of MECP2 in
neurons can lead to a decrease in AKT signaling (Li et al.,
2013). A similar pattern was observed here in mutant neu-
rons generated from Rett patient hiPSCs as measured by
phosphorylation of AKT and S6, while hiPSCs themselves
did not seem to be affected by loss of MECP2 (Figure 1E).
Dendritic complexity has been shown extensively to be
reliant onMECP2 expression in variousmodels of Rett syn-
drome, and we found a statistically significant decrease in
complexity in neurons made in the absence of MECP2 by
Sholl assay (Figure 1F). In addition, we observed qualitative
differences in basic neuronalmorphology betweenWTand
mutant neurons, where the neurons lacking MECP2 had
shorter, thicker processes, and their soma was not as well
defined.Vitro
7) heterozygous for MECP2 mutations exhibit a mosaic pattern of
a typical Yamanaka protocol yielding individual isogenic clones with
ANOG and OCT4 staining.
progenitor cells yielded homogeneous cultures of NPCs with and
rd neurons and glia by growth factor withdrawal as measured by
blot with antibodies that recognize the active forms of Akt and its
UT neurons derived from patient 982.
SEM. Scale bars on images indicate 10 mm.
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Loss of MECP2 Affects the Transcriptome of Neurons
It has been suggested that loss of MECP2 only affects gene
expression in neurons as opposed to the hPSCs and NPCs
from which they were derived (Li et al., 2013). We sought
to determine whether gene expression was affected in
hiPSCs, NPCs, or neurons in this patient-derived in vitro
model. To optimize the search for molecular effects of
loss of MECP2 in neurons, we generated defined neuronal
cultures by following the newly established 3i (three inhib-
itor) method to create interneurons (Figure 2A) (Maroof
et al., 2013). Interneurons are particularly relevant in the
study of Rett syndrome as interneuron-specific deletion
of Mecp2 in mice recapitulates many of the disease symp-
toms (Ito-Ishida et al., 2015; Tomassy et al., 2014). We vali-
dated the quality of differentiation at each step by immu-
nostaining for markers typical of particular cell types
(SOX2, SOX1, and NESTIN as well as FOXG1 and NKX2.1
for NPCs; and Tuj1, MAP2, and GABA for interneurons)
in both WT and MUT cultures followed by quantification
(Figures S4A and S4B). While methods for derivation
from pluripotent stem cells are effective at making inter-
neurons, these cultures are not pure. As such, we first
ensured that the proportion of neurons present in the cul-
tures for comparison were not consistently different (Fig-
ure S4C). We then assessed whether interneurons lacking
MECP2 also showed diminished dendritic branching. In
fact, in patient-derived interneurons made by 3i, defects
in dendritic branching as measured by the number of end-
points were clearly observed (Figure 2A).
We therefore proceeded with deep RNA sequencing
(RNA-seq; >120 million reads per sample) of hiPSC, NPC,
and interneuron cultures. With such sequencing depth, it
was possible to analyze the RNA-seq reads for the known
mutations present in the patients from which these lines
were made (Figure S4D). This analysis demonstrated that
each line studied expressed strictly either theWTormutant
allele of MECP2, and that XCI status was unchanged even
after extensive differentiation to neurons. We quantified
the expression level ofMECP2 inWTcells across these three
stages of development and found that the average reads perFigure 2. Loss of MECP2 Is Associated with Differential Gene Exp
(A) Immunostaining neurons generated from patient 982 for TuJ
complexity by counting endpoints.
(B) Volcano plots of differentially expressed genes (DEGs) in hiPSCs,
(C) Gene ontological analysis of DEGs increased versus decreased in M
(D) An examination of SASP genes in neurons.
(E) Patient skin-derived clones of fibroblasts lacking MECP2 showed s
(F) Top: the senescence assay applied to neural progenitors derived
Bottom: patient-derived neuronal cultures showed a strong increase
shown on the right).
(G) RT-PCR for P53 targets after siRNA treatment of WT neurons.
Bar graphs represent means ± SEM. *p < 0.05. Scale bars on images ikilobase of transcript per million mapped reads RPKM was
3.1 for hiPSCs, 4.3 for NPCs, and 7.75 for interneuron-en-
riched cultures. This is consistent with consensus that
MECP2 is enriched in neuronal cells, but also demonstrates
that it could potentially be relevant to hiPSC and NPC
physiology as well. However, high stringency analyses
(false discovery rate <0.05) of the RNA-seq data yielded
very few gene expression changes due to loss of MECP2
in hiPSCs or NPCs derived from Rett patients (Figure 2B),
consistent with Li et al. (2013). On the other hand,
interneuron cultures made from patient 982 showed
many gene expression changes when comparing two indi-
vidual WT and MUT clones (Figure 2B). Gene ontology
analysis uncovered many neuronal physiology-related
pathways that were downregulated due to loss of MECP2
in neurons, while genes associated with extracellular re-
modeling and cell migration appeared to be induced
(Figure 2C).
Probing the RNA-seq data, we also found that MECP2
null interneuron cultures showed a strong increase in a
group of genes that are known to be induced by senescent
cells, known as the senescence-associated secretory pro-
gram (SASP). The vast majority of SASP genes that were
changed in MECP2 null neurons were upregulated as
opposed to downregulated, suggesting a robust pattern of
SASP induction (Figure 2D). The only previous report link-
ing MECP2 loss to senescence was performed by partial
silencing of this protein in mesenchymal stem cells, but
the results were consistent with those shown here for pa-
tient-derived MECP2 null fibroblasts (Squillaro et al.,
2010). The induction of SASP was intriguing in light of
the fact that, while attempting tomake clones of fibroblasts
from patients with Rett syndrome, we repeatedly found
that clones lacking MECP2 did not expand well after pas-
sage (14 MECP2 null clones were created, none expanded),
while clones expressing the WT allele expanded without a
problem (42MECP2+ clones were created, we attempted to
expand four of them, and all four expanded).
To determine whether MECP2 null fibroblasts encounter
senescence, we performed an assay to detect endogenousression in Neurons
1, a neuronal-specific marker. Right: quantification of dendritic
NPCs, and neurons.
ECP2 null neurons.
trong b-gal activity, while those of WT fibroblasts did not.
from Rett patients did not show significant senescence activity.
in the absence of MECP2 (quantification across independent lines
ndicate 10 mm.
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beta-galactosidase activity, which is known to be a hall-
mark of this process (Wang et al., 2013). Indeed, MECP2
null fibroblasts showed strong activity in this senescence
assay (Figure 2E). We did not encounter such difficulties
with clonal expansion once hiPSCs or hiPSC-derived
NPCs were made from patients, presumably because dur-
ing reprogramming, telomerase is strongly induced to
restore telomere length at least beyond the critical
threshold (Marion et al., 2009; Suhr et al., 2009). In fact,
our RNA-seq data showed that hiPSCs made from patients
had very high expression of TERT, and NPCs still ex-
pressed moderate levels, while neurons did not express
appreciable levels (average RPKM for TERT: hiPSC, 8.8;
NPC, 1.6; neuron, 0.006). Importantly, the same endoge-
nous galactosidase activity assay on interneurons showed
a dramatic increase in senescence activity in neurons lack-
ing MECP2 (Figure 2F). These data indicate that loss of
MECP2 leads to not only induction of SASP but also a
bona fide senescence program in neurons.
Induction of P53 in the Absence of MECP2
Cellular senescence programs are known to be regulated by
P53, which can then activate various response pathways
downstream, such as DNA repair and apoptosis (Vaziri
and Benchimol, 1996). Interestingly, P53 induction due
to telomere shortening was previously shown to cause de-
fects in dendritic branching (Ferron et al., 2009), which is
also the dominant phenotype in Rett syndrome. To begin
to look for hallmarks of P53 induction in the absence of
MECP2, we performed RT-PCR for P53-related targets in
cells with silencing of MECP2 by siRNA (Figure S4E). This
assay suggested that decreased MECP2 levels led to induc-
tion of P53-related target genes such as P21, GADD45,
DDIT4, and DDB2 (Figure 2G).
To determine the effect of loss of MECP2 in relation to
cell-stress pathways at the protein level, we performed im-
munostaining for H2AX, PML, P53, and P21 in neurons
with and without MECP2. Staining for each of these
markers showed strong increases in expression/levels of
these markers of cell stress in patient-derived NPCs, neu-
rons, and also after silencing of MECP2 in both NPCs and
neurons (Figures 3A–3D). WT NPCs with silencing ofFigure 3. Loss of MECP2 Leads to Induction of DNA Damage and
(A) Immunostaining of patient NPCs, NPCs with siRNA against MECP2, a
of MECP2.
(B) Immunostaining of patient NPCs, NPCs with siRNA against MECP2
(C) Immunostaining for P53 and p21, a target of P53.
(D) Immunostaining after siRNA silencing of MECP2 in WT neuronal c
(E) Treatment of MECP2 null neurons with DMSO or Pifithrin, follow
dendritic branching. Bottom left: RT-PCR for GADD45, a P53 target
quantification of branching phenotype across three independent exp
*p < 0.05 according to Student’s t test. Bar graphs represent means ±MECP2 by siRNA and neurons lacking MECP2 also showed
clear induction of these marks.
Blocking Induction of P53 Can Rescue Dendritic
Branching Defects Due to Loss of MECP2
Previous evidence from a murine model of telomere short-
ening as a result of loss of telomerase complex (TERT) led to
defects in dendritic branching, and this effect was strictly
dependent on induction of P53 (Ferron et al., 2009). A
more recent study also showed that experimentally aging
the neural lineage with telomerase inhibition led to neu-
rons with signs of aging, including reduced dendritic
branching (Vera et al., 2016). Therefore, we posited that in-
hibition of P53 in MECP2 null neurons could potentially
restore appropriate dendritic branching. To determine
whether blocking the action of P53 could improve den-
dritic branching in MECP2 null interneurons, we took
advantage of Pifithrin-a, a potent inhibitor of P53 target
gene activation (Bassi et al., 2002). Treatment of MECP2
null interneurons with Pifithrin-a showed evidence of
P53 inhibition as measured by RT-PCR for GADD45 (Vaziri
and Benchimol, 1996), a target gene important for DNA
repair (Figure 3E). After 24–48 hr of P53 inhibition by Pifi-
thrin-a, MECP2 null interneurons appeared to adopt an
improved neuronal morphology typified by increased
physical distinction between the soma and neurites,
longer, thinner neurites, as well as increased dendritic
branching as shown and quantified in Figure 3E. These
data provide evidence that neuronswithoutMECP2 induce
P53 activity, which then inhibits the formation of complex
neuronal processes.
To determine whether any of the phenotypes discovered
in this in vitromodel of Rett syndromehave relevance to pa-
tients afflicted with the disease, we acquired tissue speci-
mens fromRett patients and age-matched controls.We first
quantified the degree of chimerism of female Rett patient
neurons due to skewing of X chromosome inactivation
to determine the relative ratio of neurons that express
MECP2 versus those that did not. Some of the Rett patient
brains showed roughly 75% of neurons lacked MECP2,
while others appeared to have less than 25% MECP2 null
neurons (Figure 4A).P53
nd patient neurons showed a strong increase in H2aX in the absence
, and patient neurons.
ultures.
ed by immunostaining with antibody for TuJ1 shows a change in
gene, showed that Pifithrin reduced P53 activity. Bottom right:
eriments.
SEM. Scale bars on images indicate 10 mm.
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Figure 4. Evidence for P53 Induction in Rett Patient Neurons in Human Brain
(A) Each Rett brain sample was assessed for the percentage of neurons with and without expression of MECP2 by immunostaining.
(B) RT-PCR on RNA isolated from Rett brain versus age-matched control brains for P53 targets.
(C) A re-analysis of data published by Gogliotti et al. (2018). Shown are a sample of P53 targets and SASP genes found on lists of genes
upregulated in Rett brain. All of these differentially expressed genes were derived using a corrected p value (false discovery rate) <0.05
from at least n = 5 samples from control and Rett brains.
Bar graphs represent means ± SEM.We performed RT-PCR on samples from some of these
brains to determine whether they showed signs of
increased P53 activity. To ensure accurate RNA representa-
tion, we first assessed the quality of the RNA from these
frozen tissues, and only proceeded with RT-PCR in sam-
ples that showed an RIN (RNA integrity number) value1460 Stem Cell Reports j Vol. 10 j 1453–1463 j May 8, 2018above 5. All the Rett patient brains we processed for
RT-PCR showed induction of canonical P53 target genes
(identified in Wei et al., 2006), consistent with what was
observed in the patient-derived neurons in vitro (Fig-
ure 4B). Recently, a new study was published that isolated
brain tissue from Rett patients and control subjects to
perform an RNA-seq profile to characterize changes spe-
cific to Rett motor cortex or cerebellum. Using data pro-
vided in that study, we found that many direct P53 targets
(as defined in Wei et al., 2006) and SASP signature genes
were upregulated in the Rett brains in both the motor cor-
tex and the cerebellum (Figure 4C).DISCUSSION
Taken together, these data demonstrate that loss of MECP2
leads to clear signs of stress such as H2AX deposition, P53/
P21 induction, and initiation of a senescence program, all
of which suggest that neurons in Rett syndrome could be
in suboptimal health, leading to neurophysiological de-
fects such as dendritic arborization (Zhou et al., 2006).
While one paper suggested that RNAi-mediated silencing
ofMECP2 could promote senescence in mesenchymal cells
(Squillaro et al., 2010), decades of work on Rett syndrome
have not uncovered a role for MECP2 in relation to senes-
cence in awide variety ofmodels such as various transgenic
mouse lines, human patient postmortem analyses, and
in vitro human models.
These results also raise the question of whether senes-
cence could be common to the etiologies of other intellec-
tual disability syndromes. The phenotypes described here
show a striking similarity to those observed in hiPSCs
and neural derivatives made from patients with immuno-
deficiency, centromeric region instability, and facial
anomalies syndrome (ICF) syndrome (Yehezkel et al.,
2013). Two independent studies showed that ICF pa-
tient-derived hiPSCs displayed telomere shortening that
was coupled to senescence of somatic derivatives such as
fibroblasts. ICF syndrome only partially overlaps with
Rett syndrome in terms of patient phenotypes, but is
caused by mutations in DNMT3B, a de novo DNA methyl-
transferase (Linhart et al., 2007). These findings together
are highly relevant as DNMT3B is a key de novo methyl
transferase to create methylated DNA (5mC), which is
the substrate for Tet oxygenase’s to create 5-hydroxmethy-
lated DNA (5hmC), which is known to be strongly bound
by MECP2 (Mellen et al., 2012). Recently, another study
showed that deletion of Tet enzymes, which are critical
to generate the 5hmC mark, led to shortened telomeres
(Yang et al., 2016), which is known to lead to P53
activation.
Another possible interpretation of these data is that
instead of a failure to mature, Rett syndrome neurons
instead show aspects of premature aging. The fact that
MECP2 null neurons show induction of aging-related
genes, including P53 targets, and induce senescence path-
ways are consistent with this idea (Tan et al., 2014). On the
other hand, while Rett patients suffer from a post-natalcognitive decline, and long-term survivors show pheno-
types associated with Parkinson disease (Zoghbi, 2016),
the typical phenotypes presented in young female patients
are not consistent with premature aging. Whether the
physiological response to loss of MECP2 is truly akin
to premature aging or whether patients suffer from effects
that are unrelated to aging is worthy of continued
investigation.EXPERIMENTAL PROCEDURES
Generation of Isogenic Rett Syndrome iPSCs
Reprogramming was performed as described (Lowry et al., 2008).
Generation of Teratomas
Generation of teratomas was previously described (Lindgren et al.,
2011).
Differentiation In Vitro and Analysis
Neural specification with neural rosette derivation, neuroprogeni-
tor (NPC) purification, and further differentiation to neurons and
glia were performed as described previously (Patterson et al., 2012,
2014).
Immunofluorescence and Image Quantification
Immunofluorescence was performed as described previously (Pat-
terson et al., 2014) and is described in detail in the Supplemental
Information.
RT-qPCR
RT-PCR with real-time PCR measurement was carried out on a
Roche 480 as described (Patterson et al., 2012, 2014). The primer
sequences are available in the Supplemental Information.
siRNA Gene Silencing
All knockdown experiments were performed as described previ-
ously (Patterson et al., 2014).
b-Galactosidase Senescence Assay
b-Galactosidase senescence assay was performed using the Senes-
cence b-Galactosidase Staining Kit from Cell Signaling. The num-
ber of blue cells and number of total cells were quantified using
the Cell Counter plugin in ImageJ.
Quantification of Dendritic Arborization
The stained cells were then imaged at 203, and dendritic arbors
of individual cells were traced using the Simple Neurite Tracer
plugin for ImageJ. The number of process ends per cell were
counted using the Cell Counter plugin for ImageJ. The num-
ber of process ends per cell are presented as mean ends per
cell ± SEM.
RNA Expression Profiling
RNA-seq was performed as described previously (Gu et al., 2016).
These data are available from NIH dataset GEO: GSE107399.Stem Cell Reports j Vol. 10 j 1453–1463 j May 8, 2018 1461
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